Lancet Rheumatology: Tocilizumab monotherapy for giant cell arteritis after ultra-short glucocorticoid administration: a single-arm, open-label, proof-of-concept study

background

Background background

Two randomized controlled trials have shown that tocilizumab has the effect of reducing the use of glucocorticoids in patients with giant cell arteritis

Two randomized controlled trials have shown that tocilizumab has the effect of reducing the use of glucocorticoids in patients with giant cell arteritis

method

Method method

The researcher-initiated, single-arm, single-center, open-label, proof-of-concept test, using a Simon two-stage design, was completed at the Bern University Hospital in Bern, Switzerland

The researcher-initiated, single-arm, single-center, open-label, proof-of-concept test, using a Simon two-stage design, was completed at the Bern University Hospital in Bern, Switzerland

Result result

From 2018 Nian 11 Yue 23 Ri to 2019 Nian 9 Yue 22 days, recruited 18 patients (of which 12 are women, 18 per capita is white), the median age was 72 (IQR 67-75) years old

From 2018 Nian 11 Yue 23 Ri to 2019 Nian 9 Yue 22 days, recruited 18 patients (of which 12 are women, 18 per capita is white), the median age was 72 (IQR 67-75) years old

Meaning meaning

Data show that in newly diagnosed patients with giant cell arteritis, tocilizumab has a slow induction of remission and a long-lasting remission maintenance effect after ultrashort pulses of glucocorticoids

Data show that in newly diagnosed patients with giant cell arteritis, tocilizumab has a slow induction of remission and a long-lasting remission maintenance effect after ultrashort pulses of glucocorticoids

Reference:

Lisa Christ, Luca Seitz, Godehard Scholz, Adela-Cristina Sarbu, Jennifer Amsler, Lukas Bütikofer, Christoph Tappeiner, Florian Kollert, Stephan Reichenbach, Peter M Villiger .

Lisa Christ, Luca Seitz, Godehard Scholz, Adela-Cristina Sarbu, Jennifer Amsler, Lukas Bütikofer, Christoph Tappeiner, Florian Kollert, Stephan Reichenbach, Peter M Villiger .
Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm arteritis , open-label, proof-of-concept study.
Lancet Rheumatol.
2021 July 02.
https://doi.
org/10.
1016/S2665-9913(21)00152-1 .
https://doi.
org/10.
1016/S2665 -9913(21)00152-1

leave a message here